Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen,

Advanced Treatment Methods, Significant Study Results, Conferences, and Final
       Study Data Releases - Research Report on Amgen, Celgene, Vertex
           Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 18, 2013

NEW YORK, June 18, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Amgen
Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG), Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD),
and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Amgen Inc. Research Report

On June 13, 2013, Amgen Inc. (Amgen) announced that the US Food and Drug
Administration (FDA) has sanctioned a new indication for XGEVA (denosumab) for
the treatment of adults and skeletally mature adolescents with giant cell
tumor of bone (GCTB) that is unresectable or where surgical resection is
likely to result in severe morbidity. XGEVA was accredited following a
priority review by the FDA. "With today's XGEVA FDA approval, Amgen can offer
a much needed treatment option to patients who suffer from giant cell tumor of
bone that cannot be adequately treated with surgery. Advances in our
understanding of the underlying biology of this rare disorder have allowed
Amgen to generate compelling clinical evidence to address the medical needs of
patients and their healthcare providers," shared Sean E. Harper, M.D.,
Executive Vice President of Research and Development at Amgen. The Full
Research Report on Amgen Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/e763_AMGN]

--

Celgene Corporation Research Report

On June 13, 2013, Celgene Corporation (Celgene) announced findings from PALACE
3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR,
the European Congress of Rheumatology annual meeting in Madrid, Spain. The
PALACE 3 study (evaluating 495 patients) demonstrated statistical significance
in achieving the primary endpoint of American College of Rheumatology (ACR) 20
score at week 16 for patients receiving apremilast compared to placebo (PBO),
(PBO, 19%; apremilast 20 mg BID, 29%; apremilast 30 mg BID, 43%; p<0.05 and
p≤0.0001, respectively). Patients in the 30 mg BID active treatment arm also
showed significant and sustained advancements in psoriasis-related endpoints,
including Psoriasis Area Severity Index (PASI) 50 and PASI-75 at week 24.
Comparable improvements in 30 mg BID-treated patients were also perceived in
key secondary endpoints, including various measures of physical function,
signs and symptoms, and quality of life. The Full Research Report on Celgene
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/7541_CELG]

--

Vertex Pharmaceuticals Incorporated Research Report

On June 5, 2013, Vertex Pharmaceuticals Incorporated (Vertex Pharmaceuticals)
announced that six abstracts from its cystic fibrosis (CF) program will be
presented at the 36th European Cystic Fibrosis Society (ECFS) Conference in
Lisbon, Portugal, June 12-15, 2013. Presentations will include data from
Cohorts 2 and 3 of a Phase 2 study of lumacaftor (VX-809) combined with
ivacaftor in people with the most common mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, F508del, as well as data from
a Phase 2 study of VX-661 combined with ivacaftor in people with two copies of
the F508del mutation. Poster presentations will feature data on the use of
KALYDECO (ivacaftor) in people with CF of ages 6 and older who have the G551D
mutation will follow. The accepted abstracts have been published by the
Journal of Cystic Fibrosis on the same date, and can be accessed at the
"Session Planner" on the ECFS Conference website. Following these
presentations, the slides will be available on the ECFS Conference website.
The Full Research Report on Vertex Pharmaceuticals Incorporated - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/ec92_VRTX]

--

MannKind Corp. Research Report

On June 11, 2013, MannKind Corp. (MannKind) announced that it will participate
at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference
on Tuesday, June 18, 2013 at 2:55 p.m. (ET) at the InterContinental Hotel in
Boston. Interested parties can access through a link to the live webcast of
the presentations provided in the News & Events section of the Company's
website. The Full Research Report on MannKind Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/0b44_MNKD]

--

Peregrine Pharmaceuticals Inc. Research Report

On June 3, 2013, Peregrine Pharmaceuticals Inc. (Peregrine Pharmaceuticals)
reported final data from its randomized, double-blind, placebo-controlled
Phase II trial of bavituximab in patients with second-line non-small cell lung
cancer (NSCLC). An improvement in median overall survival (OS) of 11.7 months
in the 3 mg/kg bavituximab plus docetaxel arm compared to 7.3 months in the
combined control arm, with a persistent separation in the Kaplan Meier
survival curves (HR=0.662) were seen in the final results from the Phase II
trial. "Immunotherapies have shown significant promise in treating solid
tumors and it is encouraging to see these latest results from bavituximab in
second-line NSCLC. Bavituximab is a unique targeted immunotherapy with a novel
mechanism of action that potentially synergizes well with other compounds
currently being developed for oncology. I look forward to being involved in
the upcoming Phase III trial and to seeing the potential of bavituximab in
other indications and combinations," said Martin J. Edelman, M.D., Professor
of Medicine at the University of Maryland Greenebaum Cancer Center. The Full
Research Report on Peregrine Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/df4a_PPHM]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)